Total results651
Search criteria
Number of publications supporting the inclusion of this protein in EV MemProt Atlas.
Annotation confidence score; open for threshold definitions.
Extremely high >= 0.70High >= 0.60Medium >= 0.40Low >= 0.30| UniProt ID | Protein names | Protein classification | Transmembrane count | Related Diseases | Mediation categories | Download | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| AMPN | P15144 | Aminopeptidase N (AP-N) (hAPN) (EC 3.4.11.2) (Alanyl aminopeptidase) (Aminopeptidase M) (AP-M) (Microsomal aminopeptidase) (Myeloid plasma membrane glycoprotein CD13) (gp150) (CD antigen CD13) | CD markersEnzymesMetabolic proteins | 1 | Psoriasis | Clinical-translation mediationFusion and delivery mediationImmune mediation | 1 | 0.53 | ||
| ANK2 | Q01484 | Ankyrin-2 (ANK-2) (Ankyrin-B) (Brain ankyrin) (Non-erythroid ankyrin) | Disease related genesHuman disease related genesPlasma proteins | Long QT syndrome | Fusion and delivery mediationImmune mediationMetabolism mediation | 1 | 0.53 | |||
| ANKL2 | Q86XL3 | Ankyrin repeat and LEM domain-containing protein 2 (LEM domain-containing protein 4) | Disease related genesEssential proteinsHuman disease related genes | 1 | Primary microcephaly | Receptor-signaling mediation | 1 | 0.53 | ||
| ANO5 | Q75V66 | Anoctamin-5 (Gnathodiaphyseal dysplasia 1 protein) (Transmembrane protein 16E) | Disease related genesHuman disease related genesPotential drug targets | 8 | Limb-girdle muscular dystrophyOsteogenesis imperfecta | Clinical-translation mediationFusion and delivery mediationImmune mediation | 1 | 0.53 | ||
| AQP1 | P29972 | Aquaporin-1 (AQP-1) (Aquaporin-CHIP) (Channel-like integral membrane protein of 28 kDa) (Urine water channel) | Blood group antigen proteinsMetabolic proteinsPredicted membrane proteins | 6 | Lips/oral mucosa miscellaneous disorder | Clinical-translation mediationFusion and delivery mediationMetabolism mediation | 1 | 0.53 | ||
| ASIC1 | P78348 | Acid-sensing ion channel 1 (ASIC1) (Amiloride-sensitive cation channel 2, neuronal) (Brain sodium channel 2) | 2 | Heart failurePain | Clinical-translation mediationFusion and delivery mediation | 1 | 0.53 | |||
| CA2D1 | P54289 | Voltage-dependent calcium channel subunit alpha-2/delta-1 (Voltage-gated calcium channel subunit alpha-2/delta-1) [Cleaved into: Voltage-dependent calcium channel subunit alpha-2-1; Voltage-dependent calcium channel subunit delta-1] | FDA approved drug targetsPlasma proteinsPredicted intracellular proteins | 1 | EpilepsyIntellectual disabilityAnxiety disorder | Clinical-translation mediationFusion and delivery mediation | 1 | 0.53 | ||
| CA2D2 | Q9NY47 | Voltage-dependent calcium channel subunit alpha-2/delta-2 (Voltage-gated calcium channel subunit alpha-2/delta-2) [Cleaved into: Voltage-dependent calcium channel subunit alpha-2-2; Voltage-dependent calcium channel subunit delta-2] | Disease related genesFDA approved drug targetsPredicted intracellular proteins | 1 | Epilepsy | Adhesion and uptake mediationClinical-translation mediationFusion and delivery mediation | 1 | 0.53 | ||
| CAC1C | Q13936 | Voltage-dependent L-type calcium channel subunit alpha-1C (Calcium channel, L type, alpha-1 polypeptide, isoform 1, cardiac muscle) (Voltage-gated calcium channel subunit alpha Cav1.2) | Disease related genesFDA approved drug targetsHuman disease related genes | 24 | AutismAutism spectrum disorderBrugada syndrome | Clinical-translation mediationFusion and delivery mediationMetabolism mediation | 1 | 0.53 | ||
| CAC1E | Q15878 | Voltage-dependent R-type calcium channel subunit alpha-1E (Brain calcium channel II) (BII) (Calcium channel, L type, alpha-1 polypeptide, isoform 6) (Voltage-gated calcium channel subunit alpha Cav2.3) | 24 | Heart failureUnspecific body region injury | Clinical-translation mediationFusion and delivery mediationMetabolism mediation | 1 | 0.53 |